S&P 500 Healthcare Sector SEC Filings — October 26, 2026

Director Guthart sold 20,095 shares at $451.61 (~$9.08M), leaving 1,204,530 shares held; executed under a 10b5-1 plan, so signal weight is limited

VP Corporate Controller Widman sold 4,047 shares at $453.21 (~$1.83M) across 23 reported transactions after several option exercises at $229.39–$304.67; retains 1,026 shares, a small residual stake

Director Barratt sold 1,150 shares at $443.80 (~$510K) after exercising options at $90.49, retaining 1,150 shares, indicating a near-complete exit of the option-linked position

SVP Chief HR Officer Wadors sold 1,078 shares at $443.80 (~$478K) under a 10b5-1 plan, a routine-scale sale for a senior executive

Four separate insider filings on a single day, with sales clustered around $443–$453, suggests coordinated liquidity activity or a shared trading window; price cluster is a useful reference point

13F-HR for quarter ended Sep 30, 2026 discloses 15 positions with Protagonist Therapeutics (~$345.07M) and MeiraGTx (~$73.05M) as largest holdings, signaling concentrated conviction in clinical-stage biotech

Positions such as Adicet Bio (~$0.16M) and VOR Biopharma (~$1.03M) are very small, suggesting strategic or exploratory stakes rather than core conviction

14 of 15 positions reported with full sole discretionary voting authority, indicating direct control and clean governance of the venture book

Aggregate disclosed sales of ~$11.9M by four insiders in a single filing cycle; although 10b5-1-planned, clustering may draw negative sentiment from investors

Director Guthart's ~$9.08M sale is the largest single disclosure and represents a meaningful portion of his holdings, warranting monitoring for further sales under the same plan

Barratt and Widman exercised and immediately sold options, a pattern that increases share supply without signaling new capital commitment

Standard BioTools is reported with 311,967 shares but sole voting authority of 0, a reporting inconsistency that may warrant verification against the filing

Protagonist Therapeutics dominates reported value, so the portfolio's performance is heavily dependent on a single clinical-stage biotech

The book is weighted toward early-stage life sciences names, implying elevated binary-outcome risk and valuation volatility

Neither filing set provides YoY or QoQ financial comparisons, so fundamental deterioration cannot be assessed from this batch

Sales executed at ~$443–$453 under 10b5-1 plans suggest these are scheduled rather than discretionary; an investor might treat the price cluster as a reference level and look for entry near support if fundamentals hold

Largest JJDC position (~$345.07M reported value) signals strategic validation of the asset; a clinical or partnering catalyst could re-rate the holding

~$73.05M position in a gene-therapy name provides a second concentrated bet; any positive regulatory or partnering news would benefit the strategic holder

~$26.56M stake may indicate an early-stage partnership pipeline that could convert to larger strategic exposure

Repeated exercise-and-sell activity at ~$90–$300 strike prices shows insiders have realized large in-the-money gains, which can be a sentiment proxy for stock appreciation over multi-year horizons

Tiny positions such as Adicet Bio (~$0.16M) could be exited or consolidated, a potential source of incremental capital for higher-conviction names

Four of four Intuitive Surgical filings are 10b5-1-planned sales totaling ~$11.9M, illustrating how pre-scheduled plans dominate large-cap medtech insider activity and dilute signal value

Multiple insiders exercised options and sold the underlying shares on the same day, a common pattern that increases apparent selling pressure without indicating a change in long-term conviction

JJDC's 13F shows a concentrated book in early-stage therapeutics, reflecting strategic-investor preference for binary-outcome bets with potential partnering upside

Multiple insider sales at similar prices point to a defined trading range that can serve as a reference for near-term technical analysis across the medtech name

None of the five filings provides guidance, capital allocation, or period-over-period financial data, limiting fundamental analysis and pointing to the need for earnings-release cross-checks

Monitor for further sales from Guthart and Widman under the same 10b5-1 plans; a shift from plan-based to discretionary selling would be a more meaningful signal

Cross-check insider activity against upcoming results and any guidance updates, as earnings commentary will provide the period-over-period context missing from these filings

Track clinical and regulatory milestones for the largest reported holding (~$345.07M), as any readout will materially move the JJDC position

Watch for gene-therapy regulatory updates affecting the ~$73.05M position

Verify the Standard BioTools voting-authority discrepancy (sole = 0 despite 311,967 shares) against the source 13F before relying on the data

The following quarterly filing will show whether the small positions (Adicet Bio, VOR Biopharma) were added to or exited, providing the period-over-period comparison this batch lacks